Abstract
Prolidase deficiency (PD) is a rare recessive disorder resulting from mutations in the prolidase gene (PEPD); only 17 causative mutant alleles had been so far characterized. Prolidase is a ubiquitous enzyme that hydrolyses dipeptides with C-terminal proline or hydroxyproline residues and indeed, lack of this enzyme activity causes massive urine excretion of undigested iminodipeptides. The clinical manifestations of PD are widely variable, and include intractable skin ulcers, unusual face, different degree of mental retardation, and recurrent infections. No definitive treatment is at present available.
We report an 8-year girl with a typical PD facies, normal intelligence, and recurrent deep ulcerations complicated by infections. She was found to be compound heterozygous for two novel mutations in PEPD, c.1133delACG and c.1301delT, affecting the C-terminal end of the enzyme where the active site is located. Given her life-threatening course, she underwent allogeneic hematopoietic stem cell transplantation (HSCT) from her HLA-identical brother, confirmed heterozygous for the c.1133delACG allele. Successful engraftment was documented by full-donor chimerism. Posttransplant monitoring of erythrocyte prolidase activity showed that the child had converted to a heterozygous pattern. Reduction of excreted urine dipeptides, evaluated by capillary electrophoresis, supported the effectiveness of the treatment. Unfortunately the patient died on day +92 of invasive fungal infection.
Despite the unfavorable outcome, we provide the first evidence that HSCT has the potential to reverse some of the biochemical features of PD patients. The indication to transplant must be balanced against the clinical manifestation of individual patients.
Competing interests: None declared.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- ALT:
-
Alanine aminotransferase
- AST:
-
Aspartate aminotransferase
- HLA:
-
Human leukocyte antigen
- HSC:
-
Hematopoietic stem cells
- HSCT:
-
Hematopoietic stem cell transplantation
- PRBC:
-
Packed red blood cells
References
Archuleta TD, Devetten MP, Armitage JO (2004) Hematopoietic stem cell transplantation in hematologic malignancy. Panminerva Med 46(1):61–74
Berardesca E, Fideli D, Bellosta M, Dyne KM, Zanaboni G, Cetta G (1992) Blood transfusions in the therapy of a case of prolidase deficiency. Br J Dermatol 126(2):193–195
Besio R, Alleva S, Forlino A et al (2009) Identifying the structure of the active sites of human recombinant prolidase. Eur Biophys J 5:5
Boelens JJ, Rocha V, Aldenhoven M, et al. on behalf of EUROCORD, Inborn Error Working Party of EBMT and Duke University (2009). Risk Factor Analysis of Outcomes after Unrelated Cord Blood Transplantation in Patients with Hurler Syndrome. Biol Blood Marrow Transplant; 15:618–625
Chinard FP (1952) Photometric estimation of proline and ornithine. J Biol Chem 199(1):91–95
Davis GE, Sheard C (1927) The spectrophotometric determination of hemoglobin. Arch Intern Med 40:226–236
Forlino A, Lupi A, Vaghi P et al (2002) Mutation analysis of five new patients affected by prolidase deficiency: the lack of enzyme activity causes necrosis-like cell death in cultured fibroblasts. Hum Genet 111(4–5):314–322
Ledoux P, Scriver C, Hechtman P (1994) Four novel PEPD alleles causing prolidase deficiency. Am J Hum Genet 54(6):1014–1021
Lochs H, Morse EL, Adibi SA (1990) Uptake and metabolism of dipeptides by human red blood cells. Biochem J 271(1):133–137
Lupi A, Casado B, Soli M et al (2002) Therapeutic apheresis exchange in two patients with prolidase deficiency. Br J Dermatol 147(6):1237–1240
Lupi A, De Riso A, Torre SD et al (2004) Characterization of a new PEPD allele causing prolidase deficiency in two unrelated patients: natural-occurrent mutations as a tool to investigate structure-function relationship. J Hum Genet 49(9):500–506
Lupi A, Rossi A, Vaghi P, Gallanti A, Cetta G, Forlino A (2005) N-benzyloxycarbonyl-L-proline: an in vitro and in vivo inhibitor of prolidase. Biochim Biophys Acta 1744(2):157–163
Lupi A, Tenni R, Rossi A, Cetta G, Forlino A (2008) Human prolidase and prolidase deficiency: an overview on the characterization of the enzyme involved in proline recycling and on the effects of its mutations. Amino Acids 35(4):739–752
MacMillan ML, Davies SM, Nelson GO et al (2008) Twenty years of unrelated donor bone marrow transplantation for pediatric acute leukemia facilitated by the national marrow donor program. Biol Blood Marrow Transplant 14(9 Suppl):16–22
Massberg S, von Andrian UH (2009) Novel trafficking routes for hematopoietic stem and progenitor cells. Ann N Y Acad Sci 1176:87–93
Myara I, Charpentier C, Lemonnier A (1982) Optimal conditions for prolidase assay by proline colorimetric determination: application to iminodipeptiduria. Clin Chim Acta 125(2):193–205
Odoom JE, Campbell ID, Ellory JC, King GF (1990) Characterization of peptide fluxes into human erythrocytes. A proton-n.m.r. study. Biochem J 267(1):141–147
Prasad VK, Kurtzberg J (2008) Emerging trends in transplantation of inherited metabolic diseases. Bone Marrow Transplant 41(2):99–108
Royce PM, Steinman B (2002) Prolidase deficiency. In: Royce PM, Steinman B (eds) Connective tissue and its heritable disorders. Wiley-Liss, New York
Trounson A (2009) New perspectives in human stem cell therapeutic research. BMC Med 7(29):29
Acknowledgments
This work was supported by MIUR 2008 (2008XA48SC), by Fondazione Cariplo 2007 to A.F. and by Progetto Regione Lombardia (cod. SAL/45) “Dalla scienza dei materiali alla medicina molecolare” to A.F., A.R., and E.D.L.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
Communicated by: Jean-Marie Saudubray.
Electronic Supplementary material
Appendices
Short Summary
Two novel causative mutations were documented in a patient with Prolidase Deficiency (PD), a rare autosomal recessive disease of connective tissue for which only 17 mutant causative alleles had been reported. No therapies with curative potential are available for PD patients; this is the first report of HSCT with at least partial rescue of this disease. Reversal of enzyme activity and urine dipeptides excretion suggested that PD could be added to the disorders treatable by transplantation.
Accession Codes: OMIM: 170100 (Prolidase Deficiency); E.C.: 3.4.13.9 (Prolidase); HUGO: PEPD (Proliase); GeneBank: NM_000285.3 (Prolidase mRNA)
Contributions of Individual Authors
-
Rolando Cimaz made initial diagnosis and designed therapeutic approach
-
Maurizio Aricò Désirée Caselli: took care of the evaluation of the feasibility and then of performing HSCT transplantation
-
Silvia Riva Marco Spada: provided expert clinical care during the phase of severe liver failure
-
Luca Cantarini: performed the molecular characterization of the patient and her family
-
Antonella Forlino Roberta Besio, Antonio Rossi performed the molecular and biochemical characterization of the patient and determined prolidase activity at the different pre and posttransplantation time
-
Ersilia De Lorenzi Raffaella Colombo: performed the capillary electrophoresis experiments to evaluate urine dipeptide excretion following transplantation
-
Maurizio Aricò and Antonella Forlino: planned the study analyzed the data and wrote the manuscript
The guarantor for the present article is Maurizio Aricò.
All authors declare that the answers to all questions on the JMDI competing interest questionnaire are No and therefore they have nothing to declare.
Funding
This work was supported by MIUR 2008 (2008XA48SC) by Fondazione Cariplo 2007 to A.F. and by Progetto Regione Lombardia (cod. SAL/45) “Dalla scienza dei materiali alla medicina molecolare” to A.F., A.R. and E.D.L.
The authors confirm independence from the sponsors the content of the article has not been influenced by the sponsor. Informed consent for all the laboratory and genetic studies, and for treatment including HSCT was obtained from both parents.
Rights and permissions
Copyright information
© 2011 SSIEM and Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Caselli, D. et al. (2011). Partial Rescue of Biochemical Parameters After Hematopoietic Stem Cell Transplantation in a Patient with Prolidase Deficiency Due to Two Novel PEPD Mutations. In: JIMD Reports - Case and Research Reports, 2011/3. JIMD Reports, vol 3. Springer, Berlin, Heidelberg. https://doi.org/10.1007/8904_2011_62
Download citation
DOI: https://doi.org/10.1007/8904_2011_62
Received:
Revised:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-24935-8
Online ISBN: 978-3-642-24936-5
eBook Packages: MedicineMedicine (R0)